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Abstract 
In this and previous studies, we have shown p53 overexpression immunohistochemically in 14 of 17 porokeratotic 
specimens obtained from 14 lesions of nine cases, and in all six specimens of squamous cell carcinoma (SCC) arising 
on porokeratotic lesions of two cases. We screened mutations in exons 5 to 10 of the p53 gene in all these specimens 
by polymerase chain reaction-single strand conformation polymorphism analysis. Mutations of the p53 gene were 
detected in two of the six SCCs but not in any of the 17 porokeratotic specimens. These two mutations were C to 
T transitions at codons 146 and 175 in exon 5, which were a nonsense mutation at a dipyrimidine site and a missense 
mutation at a CG site, respectively. To our knowledge, neither of these mutations has been identified in skin cancers 
before. Our observations indicate that mutations of the p53 gene are not the major molecular etiology for 
porokeratosis, but are related to its skin carcinogenesis, and that p53 overexpression in porokeratosis is not due to 
p53 gene mutations. 0 1997 Elsevier Science Ireland Ltd. All rights reserved 
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1. Introduction 
Porokeratosis is a disorder of epidermal kera- 
tinization which is histologically characterized by 
the presence of a column of parakeratotic cells, 
* Corresponding author. 
called the cornoid lamella. Although the disorder 
is often familial and inherited in an autosomal 
pattern [l], its pathogenesis is not fully under- 
stood yet. Seven variants have been clinically 
distinguished: the plaque type, giant porokerato- 
sis, disseminated superficial porokeratosis (DSP), 
disseminated superficial actinic porokeratosis 
(DSAP), linear porokeratosis, porokeratosis plan- 
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Table 1 
Summary of the immunohistochemical study and p53 gene mutation analysis 
Case n0.a Age/sex Type Site 
examined 
No. of 
lesions 
examined 
No. of 
specimens 
examined 
No. of 
specime& 
showing p53 
positivity 
No. of 
specimens 
with p53 gene 
mutation 
1 55/M Plaque Forearm 1 1 0 0 
2 55/M Plaque Lower leg 1 1 1 0 
3 26/F Plaque Knee 1 I 1 0 
4 76/M Plaque Upperarm 1 1 1 0 
5 60/F Giant Hand 1 4 3 0 
see Hand 1 1 1 0 
7 76/M DSP Abdomen 1 1 1 0 
Forearm 1 1 1 0 
8 57/F DSAP Forearm 1 1 1 0 
9 61/F DSAP Lower leg I 1 1 0 
10 55/M Linear Trunk 2 2 2 0 
Leg 3 3 2 0 
see Lower leg 5 5 5 2 
“Number of cases 1 to 9 correspond to those descriped in our previous paper [16]. Case 10 was also reported previously [13]. 
bImmunohistochemical analyses in 19 of 23 specimens used in this study were performed previously [13,16]. Two anti-p53 antibodies, 
CM1 and DOl, gave the same results in the 23 specimens. 
taris palmaris et disseminata, and punctate poro- 
keratosis [1,2]. Occurrence of malignancies in 
porokeratotic lesions provides clinical evidence 
for the precancerous nature of this disease [3]. 
Abnormal DNA ploidy in the porokeratotic epi- 
dermis [4] and chromosomal instability of cul- 
tured fibroblasts derived from patients with 
porokeratosis [5,6] may contribute to the prema- 
lignant potential of porokeratosis. However, the 
precise molecular mechanism of the skin carcino- 
genesis of porokeratosis remains to be elucidated. 
Inactivation of the p53 tumor suppressor gene 
by deletions and/or mutations is a major molecu- 
lar etiology for human tumorigenesis including 
skin cancers [7,8]. Immunohistochemical detection 
of p53 protein has become a common approach 
for assessing potential p53 mutations in tumors 
[9], although the correlation between immunohis- 
tochemical overexpression of p53 and underlying 
mutations is not absolute [lO,ll]. Recent im- 
munohistochemical studies have frequently de- 
tected increased p53 expression in the epidermis 
of porokeratotic lesions [12- 161. We also ob- 
served p53 overexpression in squamous cell car- 
cinomas (SCCs) developing on porokeratotic 
lesions [ 13,161. These observations may suggest 
the involvement of p53 gene mutations in the 
etiology for porokeratosis itself and/or the subse- 
quent carcinogenesis. Genomic instabilities in 
porokeratosis [4-61 may also be induced by p53 
gene mutations, because cells with p53 gene muta- 
tions are genetically less stable [17]. To our 
knowledge, p53 gene mutations have not yet been 
studied in porokeratosis or SCC associated with 
this disease. In this study, we showed frequent p53 
overexpression in porokeratotic lesions immuno- 
histochemically. We then screened p53 gene muta- 
tions in porokeratotic lesions and SCCs arising on 
those by polymerase chain reaction-single strand 
conformation polymorphism (PCR-SSCP) analy- 
sis, and confirmed mutations by DNA sequencing 
of bands showing mobility shifts. 
2. Materials and methods 
2.1. Specimens 
Table 1 summarizes the details of specimens 
examined. Briefly, a total of 23 paraffin-embedded 
specimens were obtained from nine cases of poro- 
keratosis. These included four of the plaque type, 
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two of DSAP, one of DSP, one of giant poroker- 
atosis with an SCC, and one of linear porokerato- 
sis with multiple SCCs. The 23 specimens 
consisted of 17 porokeratotic specimens and six 
SCC specimens. The 17 porokeratotic specimens 
were obtained from 14 lesions of the nine cases. 
Of the six SCC specimens, one was obtained from 
the case of giant porokeratosis and five were 
obtained from the case of linear porokeratosis. 
Mutations in the ~53 gene were examined in all 23 
specimens. However, immunohistochemical p53 
expression was studied in four of these 23 speci- 
mens, because we had previously examined it in 
the 19 other specimens (13 porokeratotic and six 
SCC specimens) [13,16]. Of the four porokeratotic 
specimens examined immunohistochemically, 
three were obtained from three different parts of a 
lesion of giant porokeratosis (case 5 in Table 1). 
The remaining one was obtained from a patient 
with DSP (case 7 in Table 1). 
SCC were also prepared from 6-pm-thick sec- 
tions. Normal tissue DNAs were prepared from 
either dermal portions of sections or cultured 
keratinocytes obtained from unaffected skin re- 
gions of porokeratosis patients. Leukocyte DNA 
obtained from a normal subject was also used as 
a normal control. 
2.4. PCR-SSCP analysis and DNA sequencing 
2.2. Immunohistochemistry 
A rabbit polyclonal anti-p53 antiserum, CM1 
(Novocastra Lab., Newcastle upon Tyne, UK), 
and a mouse monoclonal anti-p53 antibody, DO1 
(Oncogene Science, Inc., Manhasset, NY), were 
used to detect ~53 as described previously [13,16]. 
CM1 and DO1 were applied at a dilution of 
1:lOOO and a concentration of 1 pgg/ml, respec- 
tively. In comparison with negative controls using 
normal rabbit serum for CM1 and normal mouse 
IgG for DO 1, clearly stained nuclei were regarded 
as specific staining. If a specimen had more than 
10 specifically stained nuclei in a selected field 
magnified 125 times with a Nikon X2F-EFD mi- 
croscope, it was counted as positive. Occasional 
staining was considered negative, because it has 
been found in the normal epidermis [18]. 
Mutations in exons 5 to 10 of the ~53 gene were 
first screened by PCR-SSCP analysis as previously 
described [ 11,181. Oligonucleotide primers used to 
amplify exons 5 to 10 have been described previ- 
ously [18]. PCR-SSCP was repeated at least twice 
in each case showing a mobility shift to ensure 
that the results were reproducible. Bands with 
altered migrations in SSCP analysis were ex- 
tracted from a dried gel. Eluted DNA was re-am- 
plified by PCR and used as a template for DNA 
sequencing by fluorescence-based dideoxy-termi- 
nation methods using an Applied Biosystems 
Model 373A automated DNA sequencer (Perkin 
Elmer/Applied Biosystems, Foster City, CA) as 
previously described [ 11,181. 
3. Results 
2.3. DNA preparation 
We previously studied immunohistochemical 
~53 expression in 19 (13 porokeratotic and six 
SCC specimens) of 23 specimens [13,16]. In this 
study, we examined this in four other specimens. 
Of three specimens obtained from a patient with 
giant porokeratosis, two were immunopositive 
with CM1 and DOl, and one was immunonega- 
tive with both antibodies. One specimen obtained 
from a patient with DSP was positive with these 
antibodies. Taken together with previous results 
[13,16], ~53 overexpression was detected in 14 of 
17 porokeratotic specimens and all six SCC speci- 
mens as summarized in Table 1. 
DNA was prepared from 10 paraffin-embed- PCR-SSCP analysis of DNAs prepared from 
ded, 6-pm-thick sections on microscopic glass the 17 porokeratotic specimens revealed no mobil- 
slides as previously described [11,18]. Briefly, the ity shift in exons 5 to 10 of the ~53 gene. .How- 
epidermis of porokeratotic lesions was scraped ever, two of six SCC DNAs showed mobility shift 
from glass slides with a needle under microscopic in exon 5 of the ~53 gene (Fig. 1). These two 
observation to enrich epidermal DNA. DNAs of DNAs were those from SCCs developing in a 
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patient with linear porokeratosis. Their mobility 
shift patterns were different, indicating the pres- 
ence of different mutations in these two DNAs. 
DNA sequencing of bands showing altered mi- 
grations in the two cases revealed point mutations 
at codons 146 and 175, respectively (Fig. 2). Both 
mutations were C to T transitions on the tran- 
scribed strand. The mutation at codon 146 was a 
nonsense mutation at a dipyrimidine site. Another 
mutation at codon 175 was a missense mutation 
at a CG site, which substituted histidine for 
arginine. In the previous immunohistochemical 
study [13], we regarded the SCC with a nonsense 
mutation as positive because a small cluster of 
cells stained with CM1 and DO1 were present at 
the edge of the tumor, although the majority of 
SCC cells were not stained with these antibodies. 
Fig. 2. DNA sequencing of exon 5 of the p53 gene in SCCs 
arising on porokeratotic lesions. A and B correspond to lanes 
1 and 2, respectively in Fig. 1. DNAs which were eluted from 
bands showing altered migrations in SSCP analysis, were 
subjected to DNA sequencing after re-amplification by PCR. 
Sequences of the coding strand are represented. Top, normal 
sequences of keratinocyte DNA, bottom, mutated sequences 
of DNAs from the SCCs arising on porokeratotic lesions. 
Asterisk, the base at which mutation was detected. (A) a 
missense mutation of a G to A (C to T) transition at codon 
175; (B) a nonsense mutation of a G to A (C to T) transition 
at codon 146. 
123 
In another SCC with a missense mutation, the 
majority of SCC cells were positively stained [13]. 
4. Discussion 
Fig. 1. SSCP analysis of exon 5 of the p53 gene in SCCs 
arising on porokeratotic lesions. Electrophoresis was per- 
formed in a 6% polyacrylamide gel containing 0, 5, or 10% 
glycerol. The results using a gel containing 5% glycerol are 
shown. Lane 1, an SCC specimen arising on a porokeratotic 
lesion on the lower leg of a patient with linear porokeratosis; 
lane 2, another SCC specimen arising on a different lesion on 
the lower leg of the same patient; lane 3, normal keratinocyte 
DNA from the same patient. Two bands showing mobility 
shifts in lane 2 had an identical sequence after reamplification 
(Fig. 2). Arrowhead, a band with a mobility shift. 
We have shown the overexpression of p53 in 14 
of 17 porokeratotic specimens. Other groups also 
reported frequent p53 overexpression in the epi- 
dermis of porokeratotic lesions using immunohis- 
tological methods [12,14,15]. Although 
immunohistological p53 overexpression has often 
been associated with p53 gene mutations [9], no 
mutations of the p53 gene were detected in these 
17 porokeratotic specimens by PCR-SSCP analy- 
sis. In this study, we screened p53 gene mutations 
in exons 5 to 10. Therefore, there is a possibility 
that we overlooked mutations outside these exons. 
However, mutations are infrequent outside exons 
5 to 10 [7]. It is also possible that we could not 
detect clonally expanded mutations in a small 
area of the porokeratotic epidermis, because the 
PCR-SSCP analysis used here might not have 
been sensitive enough to detect such mutations. 
Y. Ninomiya et al. 1 Journal of Dermatological Science 14 (1997) 173-I 78 171 
Despite these, the absence of p53 gene mutations 
in porokeratotic lesions indicates that p53 gene 
mutations are not the major molecular etiology 
for porokeratosis itself. 
The overexpression of p53 is induced not only 
by p53 gene mutations but also by various types 
of DNA damaging agents, including ultraviolet 
(UV) light and ionizing radiation [19]. Recent 
evidence indicates that various cellular stresses 
other than DNA damage, such as heat shock, 
osmotic shock, blockers of the cellular respiratory 
system, amino acid analogs, hydrogen peroxide, 
and heavy metals, also induce nuclear accumula- 
tion of p53 in human fibroblasts [20]. Based on 
this information, p53 overexpression may be eas- 
ily induced in porokeratosis by various cellular 
stresses, and UV light may be involved in the 
overexpression in DSAP lesions because they pre- 
dominantly develop on sun-exposed skin regions. 
The p53 gene response to DNA damage is regu- 
lated by genes other than the p53 gene as shown 
in ataxia-telangiectasia and Bloom’s syndrome 
[21,22]. Therefore, a genetic abnormality underly- 
ing porokeratosis may affect ~53 expression in 
porokeratosis. 
Although the involvement of p53 gene muta- 
tions has been clearly demonstrated in UV car- 
cinogenesis [23], it has not been studied yet in skin 
carcinogenesis associated with porokeratosis. In 
this study, we detected p53 gene mutations in two 
of the six SCC specimens arising on porokeratotic 
lesions but in none of the 17 porokeratotic speci- 
mens. The frequency of p53 gene mutations in 
these SCCs is comparable to that in SCCs etiolog- 
ically related to UV light [8]. These observations 
suggest that p53 gene mutations are responsible 
for the progression of porokeratosis to SCC at 
least in some cases. 
Mutations detected here were a nonsense muta- 
tion and a missense mutation at codons 146 and 
175 in exon 5 of the p53 gene, respectively. To our 
knowledge, these two mutations have not been 
identified in skin cancers etiologically related to 
UV light [8,10,11,23-271, although codon 175 is a 
hotspot of p53 gene mutations in internal malig- 
nancies [7]. The mutation at codon 146 was a C to 
T transition at a dipyrimidine site. Although UV 
light predominantly induces this type of mutation 
[28], it is not specific to UV mutagenesis, and it is 
induced by reactive oxygen species as well [29]. 
The mutation at codon 175 was a C to T transi- 
tion at a CG site. Mutations at this site are 
probably related to deamination of 5-methylcy- 
tosine [30]. Two SCCs carrying these different 
mutations developed on the lower leg of a patient 
with linear porokeratosis, which had rarely been 
exposed to sunlight. UV light may have had a 
small influence on the p53 gene mutations de- 
tected here. 
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